Pharmaceutical Research

, Volume 30, Issue 6, pp 1467–1468 | Cite as

Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

  • Sibylle Neuhoff
  • Geoff T. Tucker
Letter to the Editor

To the Editor:

The ‘bottom-up’ prediction of transporter-based drug-drug interactions continues to be a challenge. In this context, we offer some comments on the recent publication of Varma et al. (2012) in this Journal (1). These authors describe the development of physiologically-based pharmacokinetic (PBPK) models to predict the kinetics of pravastatin and the impact of co-medication with cyclosporine, gemfibrozil or rifampicin. While the transporter-mediated interactions with gemfibrozil and rifampicin in healthy subjects were predicted within 20% by the dynamic models, that with cyclosporine as perpetrator was significantly underestimated.

In simulating the in vivodata for pravastatin given alone, it was necessary to fit the data using empirical scaling factors for hepatic sinusoidal uptake and canalicular efflux of 31 and 0.17, respectively. With regard to the second of these scaling factors, we suggest that there is prior experimental justification for the number, based on...


Cyclosporine Rifampicin Pravastatin Gemfibrozil Absolute Abundance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res. 2012;29(10):2860–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Li N, Zhang Y, Hua F, Lai Y. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos. 2009;37(1):66–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Li N, Bi YA, Duignan DB, Lai Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm. 2009;6(4):1180–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos. 2010;38(9):1499–504.PubMedCrossRefGoogle Scholar
  5. 5.
    Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug Metab Pharmacokinet. 2012 Jan 13.Google Scholar
  6. 6.
    Rowland-Yeo K, Jamei M, Aarabi M, Rostami-Hodjegan A. Application of physiologically based pharmacokinetic (PBPK) modeling for prediction of complex drug-drug interactions (DDIs) involving OATP1B1-mediated uptake and cytochrome P450 (CYP) metabolism and multiple inhibitors. Clin Pharmacol Ther. 2012;91:S47–8.CrossRefGoogle Scholar
  7. 7.
    Abdallah AN, Billes MA, Attia Y, Doutremepuich C, Cassaigne A, Iron A. Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J. 1997;18(6):1024–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol. 2009;5(12):1469–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86(3):1154–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Perez-Villa F, Benito B, Llancaqueo M, Cuppoletti A, Roig E. Elevated levels of serum interleukin-6 are associated with low grade cellular rejection in patients with heart transplantation. Transplant Proc. 2006;38(9):3012–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, et al. Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos. 2012;40(1):93–103.PubMedCrossRefGoogle Scholar
  13. 13.
    Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006;34(10):1756–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact. 2006;159(2):156–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther. 2004;75(3):213–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000;157(5):1575–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Simcyp (Certara) Ltd., Blades Enterprise CentreSheffieldUK
  2. 2.University of Sheffield and Simcyp (Certara) Ltd.SheffieldUK

Personalised recommendations